2015
Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo
Schwab CL, English DP, Black J, Bellone S, Lopez S, Cocco E, Bonazzoli E, Bussi B, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Santin AD. Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. Gynecologic Oncology 2015, 139: 112-117. PMID: 26260909, PMCID: PMC4587290, DOI: 10.1016/j.ygyno.2015.08.002.Peer-Reviewed Original ResearchConceptsHER2/neuTreatment of HER2Efficacy of neratinibCarcinosarcoma cell lineTumor growthCell linesEffective treatment optionDeadliest gynecologic malignancyG0/G1 phaseCell cycle distributionCell signaling changesActivation of S6Neratinib treatmentGynecologic malignanciesOverall survivalTreatment optionsClinical trialsXenograft growthNew therapiesHER2NeratinibFlow cytometryNeuCycle distributionSignaling changes
2011
Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody
Raji R, Guzzo F, Carrara L, Varughese J, Cocco E, Bellone S, Betti M, Todeschini P, Gasparrini S, Ratner E, Silasi DA, Azodi M, Schwartz P, Rutherford TJ, Buza N, Pecorelli S, Santin AD. Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. Journal Of Experimental & Clinical Cancer Research 2011, 30: 106. PMID: 22075385, PMCID: PMC3224774, DOI: 10.1186/1756-9966-30-106.Peer-Reviewed Original ResearchConceptsAntibody-dependent cellular cytotoxicityAnti-Trop-2 antibodyTrop-2Cell linesEffective treatment optionChromium release assaysComplement-dependent cytotoxicityCarcinosarcoma cell lineCell surface markersOvarian carcinosarcomaTreatment optionsControl antibodyHRS7Cellular cytotoxicityHigher positivityTherapeutic strategiesHuman uterineTumor tissueFlow cytometryImmunohistochemistryRT-PCRSurface expressionAntibodiesHuman IgGCarcinosarcomaCervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody
Varughese J, Cocco E, Bellone S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Santin AD. Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. American Journal Of Obstetrics And Gynecology 2011, 205: 567.e1-567.e7. PMID: 21889762, PMCID: PMC3224189, DOI: 10.1016/j.ajog.2011.06.093.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAntibodies, MonoclonalAntigens, NeoplasmBiomarkers, TumorCarcinoma, Squamous CellCell Adhesion MoleculesCell Line, TumorComplement System ProteinsDrug Resistance, NeoplasmDrug SynergismFemaleFlow CytometryGene Expression Regulation, NeoplasticHumansImmunoglobulin GInterleukin-2Killer Cells, NaturalReal-Time Polymerase Chain ReactionUterine Cervical NeoplasmsConceptsAntibody-dependent cell-mediated cytotoxicityAnti-Trop-2 antibodyTrop-2 expressionReal-time polymerase chain reactionCell surface markersCervical cancerPolymerase chain reactionHighest messenger RNA expressionCell-dependent cytotoxicityCell-mediated cytotoxicityNovel treatment optionsChromium release assaysConventional treatment modalitiesChain reactionComplement-dependent cytotoxicityEffects of interleukinMessenger RNA expressionLevel of cytotoxicityCancer refractoryCervical carcinomaTreatment optionsTreatment modalitiesIL-2Normal cervixRelease assays
2010
High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody
Richter CE, Cocco E, Bellone S, Silasi DA, Rüttinger D, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. American Journal Of Obstetrics And Gynecology 2010, 203: 582.e1-582.e7. PMID: 20870202, PMCID: PMC2993821, DOI: 10.1016/j.ajog.2010.07.041.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntigens, NeoplasmAntineoplastic AgentsBiomarkers, TumorCell Adhesion MoleculesCell Line, TumorDrug Resistance, NeoplasmFemaleFlow CytometryHumansImmunotherapyNeoplasm StagingOvarian NeoplasmsReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSensitivity and SpecificityConceptsAntibody-dependent cell-mediated cytotoxicityComplement-dependent cytotoxicityReal-time polymerase chain reactionEpithelial cell adhesion moleculePolymerase chain reactionOvarian carcinomaInterleukin-2Cell adhesion moleculeFlow cytometryHighest messenger RNA expressionCell linesAdhesion moleculesCell-mediated cytotoxicityOvarian cancer cell linesEffective treatment optionChromium release assaysChain reactionMessenger RNA expressionCancer cell linesOvarian diseaseTreatment optionsOvarian cancerEpCAM expressionAnti-EpCAM antibodyRNA expressionHER-2/NEU overexpression in vulvar Paget disease: the Yale experience
Richter CE, Hui P, Buza N, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. Journal Of Clinical Pathology 2010, 63: 544. PMID: 20418225, DOI: 10.1136/jcp.2010.077446.Peer-Reviewed Original ResearchConceptsVulvar Paget's diseasePaget's diseaseNeu overexpressionOutcome dataHER-2/neu expressionHER-2/neuEfficacy of trastuzumabExtensive reconstructive proceduresHigh recurrence rateMedical record searchInteresting treatment optionSurgical treatmentRecurrence rateTreatment optionsNeu expressionClinical trialsReconstructive proceduresTissue microarrayPatientsRecord searchTumor samplesYale experienceDiseaseNeuStaining results